A. David Marais

7.2k total citations · 2 hit papers
130 papers, 5.0k citations indexed

About

A. David Marais is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, A. David Marais has authored 130 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Surgery, 53 papers in Endocrinology, Diabetes and Metabolism and 28 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in A. David Marais's work include Lipoproteins and Cardiovascular Health (87 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (47 papers) and Lipid metabolism and disorders (27 papers). A. David Marais is often cited by papers focused on Lipoproteins and Cardiovascular Health (87 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (47 papers) and Lipid metabolism and disorders (27 papers). A. David Marais collaborates with scholars based in South Africa, Netherlands and United States. A. David Marais's co-authors include Dirk Blom, Frederick J. Raal, Jean Firth, Daniel Gaudet, John R. Burnett, Amanda J. Hooper, Donald Moshen Tanyanyiwa, Raúl D. Santos, Gillian J. Pilcher and Ju Le Tan and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

A. David Marais

126 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

2010 692 citations Frederick J. Raal, Dirk Blom et al. profile →
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

2012 524 citations Marina Cuchel, Emma A. Meagher et al. profile →

Peers

Countries citing papers authored by A. David Marais

Since Specialization

Citations

This map shows the geographic impact of A. David Marais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. David Marais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. David Marais more than expected).

Fields of papers citing papers by A. David Marais

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. David Marais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. David Marais. The network helps show where A. David Marais may publish in the future.

Co-authorship network of co-authors of A. David Marais

This figure shows the co-authorship network connecting the top 25 collaborators of A. David Marais. A scholar is included among the top collaborators of A. David Marais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. David Marais. A. David Marais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The association between a genetic variant in the SULF2 gene, metabolic parameters and vascular disease in patients at high cardiovascular risk 2023 ·PubMed ·(unknown), Frank L.J. Visseren, Jessica van Setten, A. David Marais, Charlotte Koopal, (unknown)	1
2	Adiposity and the development of dyslipidemia in APOE ε2 homozygous subjects: A longitudinal analysis in two population-based cohorts 2021 ·Atherosclerosis ·(unknown), Frank J. Wolters, Maryam Kavousi, Eke G. Gruppen, Robin P.F. Dullaart, A. David Marais, Frank L.J. Visseren, Charlotte Koopal	13
3	The influence of glucocorticoids on lipid and lipoprotein metabolism and atherosclerosis 2014 ·South African Medical Journal ·Ian Louis Ross, A. David Marais	26
4	Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects 2014 ·Journal of the American College of Cardiology ·Gilles Lambert, Francine Petrides, Mathias Chatelais, Dirk Blom, Benjamin Choque, Fatiha Tabet, (unknown), Kerry‐Anne Rye, Amanda J. Hooper, John R. Burnett, Philip J. Barter, A. David Marais	41
5	Abstract 17396: Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia 2012 ·Circulation ·Marina Cuchel, Emma A. Meagher, (unknown), Dirk Blom, A. David Marais, Robert A. Hegele, Maurizio Averna, Cesare R. Sirtori, Prediman K. Shah, Daniel Gaudet, Claudia Stefanutti, Giovanni Battista Vigna, (unknown), LeAnne T. Bloedon, Daniel J. Rader, (unknown)	3
6	Marinating beef with South African red wine may protect against lipid peroxidation during cooking 2011 ·African Journal of Food Science ·Dee Blackhurst, (unknown), (unknown), (unknown), A. David Marais	6
7	Abstract 1077: A Phase III Study of Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide (AEGR-733) in Patients With Homozygous Familial Hypercholesterolemia: Interim Results at 6 Months 2009 ·Circulation ·Marina Cuchel, Emma A. Meagher, A. David Marais, Dirk Blom, (unknown), Amanda Baer, LeAnne T. Bloedon, William J. Sasiela, Daniel J. Rader	4
8	Normal and abnormal lipid and lipoprotein metabolism 2009 ·CME/Continuing medical education ·A. David Marais	2
9	Severe Hypertriglyceridaemia as a result of Familial Chylomicronaemia 2008 ·South African Medical Journal ·(unknown), Dirk Blom, Jean Firth, Howard Henderson, A. David Marais	11
10	Simvastatin with or without ezetimibe in familial hypercholesterolemia (vol 358, pg 1431, 2008) 2008 ·New England Journal of Medicine ·John J.P. Kastelein, Fatima Akdim, E.S.G. Stroes, Aeilko H. Zwinderman, M. L. Bots, A.F.H. Stalenhoef, Frank L.J. Visseren, Eric J.G. Sijbrands, Mieke D. Trip, Evan A. Stein, Daniel Gaudet, Raphaël Duivenvoorden, Enrico P. Veltri, A. David Marais, E. de Groot	10
11	A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia 2007 ·Atherosclerosis ·A. David Marais, Frederick J. Raal, Evan A. Stein, Daniel J. Rader, James W. Blasetto, Michael K. Palmer, Wim Wilpshaar	69
12	Functional foods with added plant sterols for treatment of hypercholesterolaemia and prevention of ischaemic heart disease 2003 ·South African Journal of Clinical Nutrition ·H H Vorster, Frederick J. Raal, (unknown), A. David Marais, (unknown), Fady Ntanios	4
13	Statins in homozygous familial hypercholesterolemia 2002 ·Current Atherosclerosis Reports ·A. David Marais, Dirk Blom, Jean Firth	34
14	Chylomicron remnant metabolism in familial dyslipidemias studied with a remnant-like emulsion breath test 2001 ·Journal of Lipid Research ·T.G. Redgrave, Gerald F. Watts, Ian Martins, P. Hugh R. Barrett, John Mamo, Simon B. Dimmitt, A. David Marais	26
15	Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis 2000 ·Journal of Lipid Research ·Susanne M. Clee, Nagat Bissada, Fudan Miao, Miao Li, A. David Marais, Howard Henderson, Pieternel Steures, Janet McManus, Bruce M. McManus, Renee Leboeuf, John J.P. Kastelein, Michael R. Hayden	86
16	Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia 2000 ·Atherosclerosis ·Frederick J. Raal, Anuradha S. Pappu, D. Roger Illingworth, Gillian J. Pilcher, A. David Marais, Jean Firth, Maritha J. Kotze, Therèse Heinonen, Donald M. Black	73
17	HMG-CoA reductase is not the site of the primary defect in phytosterolemia 1998 ·Journal of Lipid Research ·G M Berger, R.J. Pegoraro, Shailendra B. Patel, (unknown), L. Rom, Hideki Hidaka, A. David Marais, A Jadhav, R.P. Naoumova, G. R. Thompson	11
18	Follow‐up on primary prevention trials 1998 ·Current Opinion in Lipidology ·A. David Marais	1
19	Variable expression of familial dysbetalipoproteinemia in apolipoprotein E2 (Lys146-->Gln) Allele carriers. 1994 ·Journal of Clinical Investigation* ·Peter de Knijff, Arn M. J. M. van den Maagdenberg, (unknown), Anton F. H. Stalenhoef, A.H.M. Smelt, John J.P. Kastelein, A. David Marais, Rune R. Frants, Louis M. Havekes	18
20	Amino acid substitution (Ile194----Thr) in exon 5 of the lipoprotein lipase gene causes lipoprotein lipase deficiency in three unrelated probands. Support for a multicentric origin. 1991 ·Journal of Clinical Investigation ·Howard Henderson, Yuxuan Ma, (unknown), María Victoria Monsalve, A. David Marais, F.K. Winkler, Klaus Gubernator, J Peterson, John D. Brunzell, Michael R. Hayden	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact